Is QTTB or XLO more profitable?

Q32 Bio has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Q32 Bio's return on equity of 149.23% beat Xilio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 149.23% 34.50% Xilio Therapeutics -58.52% -151.42% -27.61%

Which has better earnings & valuation, RNA or XLO?

Xilio Therapeutics has higher revenue and earnings than Avidity Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avidity Biosciences $36.68M 5.97 -$322.30M N/A N/A Xilio Therapeutics $43.77M 1.34 -$35.04M -$3.55 N/A

Xilio Therapeutics (XLO) Competitors

$8.90 -0.04 (-0.45%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$8.94 +0.04 (+0.45%)

As of 06/23/2026 07:38 PM Eastern

Compare

XLO vs. VYGR, KPTI, QTTB, RNA, and ALXO

Should you buy Xilio Therapeutics stock or one of its competitors? MarketBeat compares Xilio Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xilio Therapeutics include Voyager Therapeutics (VYGR), Karyopharm Therapeutics (KPTI), Q32 Bio (QTTB), Avidity Biosciences (RNA), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical products" industry.

How does Xilio Therapeutics compare to Voyager Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

In the previous week, Xilio Therapeutics' average media sentiment score of 0.00 equaled Voyager Therapeutics'average media sentiment score.

Company	Overall Sentiment
Xilio Therapeutics	Neutral
Voyager Therapeutics	Neutral

Xilio Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Xilio Therapeutics has higher revenue and earnings than Voyager Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.34	-$35.04M	-$3.55	N/A
Voyager Therapeutics	$40.37M	5.54	-$119.72M	-$1.97	N/A

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Xilio Therapeutics presently has a consensus target price of $28.00, suggesting a potential upside of 214.61%. Voyager Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 345.95%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Xilio Therapeutics has a net margin of -58.52% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

Summary

Voyager Therapeutics beats Xilio Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Xilio Therapeutics compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Karyopharm Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

Xilio Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	1.50	-$196.04M	-$15.09	N/A
Xilio Therapeutics	$43.77M	1.34	-$35.04M	-$3.55	N/A

Karyopharm Therapeutics currently has a consensus target price of $17.17, indicating a potential upside of 77.89%. Xilio Therapeutics has a consensus target price of $28.00, indicating a potential upside of 214.61%. Given Xilio Therapeutics' higher possible upside, analysts plainly believe Xilio Therapeutics is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Xilio Therapeutics has a net margin of -58.52% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

In the previous week, Karyopharm Therapeutics' average media sentiment score of 0.00 equaled Xilio Therapeutics'average media sentiment score.

Company	Overall Sentiment
Karyopharm Therapeutics	Neutral
Xilio Therapeutics	Neutral

Summary

Karyopharm Therapeutics beats Xilio Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Xilio Therapeutics compare to Q32 Bio?

Q32 Bio (NASDAQ:QTTB) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 34.5% of Q32 Bio shares are held by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Q32 Bio has higher revenue and earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	3.75	$29.82M	$2.66	4.47
Xilio Therapeutics	$43.77M	1.34	-$35.04M	-$3.55	N/A

Q32 Bio has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Q32 Bio's return on equity of 149.23% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	149.23%	34.50%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

In the previous week, Q32 Bio's average media sentiment score of 0.00 equaled Xilio Therapeutics'average media sentiment score.

Company	Overall Sentiment
Q32 Bio	Neutral
Xilio Therapeutics	Neutral

Q32 Bio currently has a consensus price target of $13.50, indicating a potential upside of 13.64%. Xilio Therapeutics has a consensus price target of $28.00, indicating a potential upside of 214.61%. Given Xilio Therapeutics' higher possible upside, analysts plainly believe Xilio Therapeutics is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Q32 Bio has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

Summary

Q32 Bio beats Xilio Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Xilio Therapeutics compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

In the previous week, Avidity Biosciences had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 2 mentions for Avidity Biosciences and 0 mentions for Xilio Therapeutics. Avidity Biosciences' average media sentiment score of 0.50 beat Xilio Therapeutics' score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Avidity Biosciences	Positive
Xilio Therapeutics	Neutral

Xilio Therapeutics has a net margin of -58.52% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Avidity Biosciences has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

54.3% of Xilio Therapeutics shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Xilio Therapeutics has higher revenue and earnings than Avidity Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	5.97	-$322.30M	N/A	N/A
Xilio Therapeutics	$43.77M	1.34	-$35.04M	-$3.55	N/A

Avidity Biosciences currently has a consensus target price of $66.81, indicating a potential upside of 421.57%. Xilio Therapeutics has a consensus target price of $28.00, indicating a potential upside of 214.61%. Given Avidity Biosciences' higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Xilio Therapeutics beats Avidity Biosciences on 8 of the 15 factors compared between the two stocks.

How does Xilio Therapeutics compare to ALX Oncology?

Xilio Therapeutics (NASDAQ:XLO) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Xilio Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

Xilio Therapeutics currently has a consensus price target of $28.00, suggesting a potential upside of 214.61%. ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 161.36%. Given Xilio Therapeutics' higher possible upside, equities analysts clearly believe Xilio Therapeutics is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Xilio Therapeutics has higher revenue and earnings than ALX Oncology. Xilio Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.34	-$35.04M	-$3.55	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by insiders. Comparatively, 21.0% of ALX Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Xilio Therapeutics' average media sentiment score of 0.00 equaled ALX Oncology'saverage media sentiment score.

Company	Overall Sentiment
Xilio Therapeutics	Neutral
ALX Oncology	Neutral

ALX Oncology has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. ALX Oncology's return on equity of -124.06% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
ALX Oncology	N/A	-124.06%	-85.57%

Summary

ALX Oncology beats Xilio Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Xilio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XLO vs. The Competition

Export

Metric	Xilio Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$58.78M	$3.45B	$6.44B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-2.51	19.75	24.66	23.99
Price / Sales	1.34	332.72	528.64	107.77
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.22	8.29	10.79	6.50
Net Income	-$35.04M	$23.85M	$3.56B	$336.88M
7 Day Performance	1.71%	2.87%	1.01%	-0.14%
1 Month Performance	7.88%	2.19%	0.43%	0.77%
1 Year Performance	-3.74%	55.48%	29.71%	28.49%

Xilio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XLO Xilio Therapeutics	2.0918 of 5 stars	$8.90 -0.4%	$28.00 +214.6%	-5.1%	$58.78M	$43.77M	N/A	70	Positive News
VYGR Voyager Therapeutics	2.2996 of 5 stars	$3.53 -2.8%	$16.50 +367.4%	+25.9%	$219.33M	$40.37M	N/A	100
KPTI Karyopharm Therapeutics	1.8117 of 5 stars	$9.10 -5.6%	$17.17 +88.6%	+122.9%	$218.47M	$151.12M	N/A	380
QTTB Q32 Bio	3.8552 of 5 stars	$12.75 -0.9%	$13.50 +5.9%	+676.5%	$218.06M	$53.74M	4.79	39
RNA Avidity Biosciences	2.5581 of 5 stars	$12.61 -1.1%	$71.25 +465.0%	-56.1%	$215.71M	$36.68M	N/A	190	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XLO) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xilio Therapeutics (XLO) Competitors

XLO vs. VYGR, KPTI, QTTB, RNA, and ALXO

How does Xilio Therapeutics compare to Voyager Therapeutics?

Summary

How does Xilio Therapeutics compare to Karyopharm Therapeutics?

Summary

How does Xilio Therapeutics compare to Q32 Bio?

Summary

How does Xilio Therapeutics compare to Avidity Biosciences?

Summary

How does Xilio Therapeutics compare to ALX Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xilio Therapeutics (XLO) Competitors

XLO vs. VYGR, KPTI, QTTB, RNA, and ALXO

How does Xilio Therapeutics compare to Voyager Therapeutics?

Does the media favor XLO or VYGR?

Which has more risk & volatility, XLO or VYGR?

Which has stronger valuation and earnings, XLO or VYGR?

Do insiders and institutionals hold more shares of XLO or VYGR?

Do analysts prefer XLO or VYGR?

Is XLO or VYGR more profitable?

Summary

How does Xilio Therapeutics compare to Karyopharm Therapeutics?

Do insiders & institutionals have more ownership in KPTI or XLO?

Which has more risk & volatility, KPTI or XLO?

Which has preferable valuation & earnings, KPTI or XLO?

Do analysts recommend KPTI or XLO?

Is KPTI or XLO more profitable?

Does the media refer more to KPTI or XLO?

Summary

How does Xilio Therapeutics compare to Q32 Bio?

Do insiders and institutionals have more ownership in QTTB or XLO?

Which has preferable earnings & valuation, QTTB or XLO?

Is QTTB or XLO more profitable?

Does the media refer more to QTTB or XLO?

Do analysts prefer QTTB or XLO?

Which has more volatility and risk, QTTB or XLO?

Summary

How does Xilio Therapeutics compare to Avidity Biosciences?

Does the media refer more to RNA or XLO?

Is RNA or XLO more profitable?

Which has more risk and volatility, RNA or XLO?

Do insiders & institutionals have more ownership in RNA or XLO?

Which has better earnings & valuation, RNA or XLO?

Do analysts recommend RNA or XLO?

Summary

How does Xilio Therapeutics compare to ALX Oncology?

Which has more risk and volatility, XLO or ALXO?

Do analysts rate XLO or ALXO?

Which has preferable valuation and earnings, XLO or ALXO?

Do institutionals and insiders have more ownership in XLO or ALXO?

Does the media prefer XLO or ALXO?

Is XLO or ALXO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools